← Back to patent-cliff list
ELV-001 (Elevara)
Tier C — Watch / tradeELV-001 (Elevara)
Teijin America Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK4, CDK6
Indications (approved)：Rheumatoid arthritis
Regional status
US
Phase II
2026-02-18
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ELV-001 (Elevara)?
Approved indications include: Rheumatoid arthritis.
When does the ELV-001 (Elevara) patent expire?
No public expiry year is available for ELV-001 (Elevara) yet; this page updates once verified.
How do I get a quote for ELV-001 (Elevara) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29